MedTrace Logo

Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype

NCT01352559 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2015-12-31

No results posted yet for this study

Summary

The purpose of this study is to determine whether pharmacogenomic study of bioamine transporters and peripheral lymphatic biomarkers(phenotype) predict antidepressant responsiveness in advance before the appearance of the drug effects until 4\~6 weeks after drug administration.

Conditions

Interventions

DRUG

responders

Antidepressants administration for 6 weeks under therapeutic dose

DRUG

non-responders

Antidepressants administration for 6 weeks under therapeutic dose

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Doh Kwan Kim, M.D., Ph.D. · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-11-30
Primary Completion
2007-03-31
Completion
2018-12-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01352559 on ClinicalTrials.gov